Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | President and COO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,802 |
Ending reported balance
After 2026-10-13 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 2 · 2026-10-09 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-10-12 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 4 · 2026-10-12 · Sale · Disposed 9,181 · Balance 380,502 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-12 · Sale · Disposed 2,700 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-10-13 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 7 · 2026-10-13 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 296,610 |
Reported balance
After 2026-10-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-09 · Exercise / conversion · Disposed 11,881 · Balance 296,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 284,729 |
Reported balance
After 2026-10-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-12 · Exercise / conversion · Disposed 11,881 · Balance 284,729 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 272,848 |
Reported balance
After 2026-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-13 · Exercise / conversion · Disposed 11,881 · Balance 272,848 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2021 Filed Feb 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 618 | $64.76 | $40,021.68 |
DisclosureSEC source: 0001209191-21-010477 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.60 to 64.90, inclusive. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,798 | $64.09 | $243,413.82 |
DisclosureSEC source: 0001209191-21-010477 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.60 to 64.58, inclusive. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,814 | $63.00 | $240,282.00 |
DisclosureSEC source: 0001209191-21-010477 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,416 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.60 to 63.42, inclusive. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,770 | $62.14 | $420,687.80 |
DisclosureSEC source: 0001209191-21-010477 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,230 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.60 to 62.58 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-010477 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,389 | $63.02 | $465,654.78 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.52 to 63.30, inclusive. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,611 | $61.81 | $470,435.91 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.31 to 62.01, inclusive. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,344 | $62.43 | $271,195.92 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.29 to 62.72, inclusive. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,656 | $61.96 | $660,245.76 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,344 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.29 to 62.28 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-009484 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-008657 · doc4.xml · derivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,850 | $60.12 | $592,182.00 |
DisclosureSEC source: 0001209191-21-008657 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.90 to 60.12, inclusive. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,150 | $59.64 | $307,146.00 |
DisclosureSEC source: 0001209191-21-008657 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,850 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.90 to 59.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-008657 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,695 | $59.25 | $396,678.75 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.00 to 59.59, inclusive. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,305 | $58.77 | $488,084.85 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,695 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.01 to 58.99, inclusive. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 910 | $60.82 | $55,346.20 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.79 to 61.05, inclusive. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,435 | $60.16 | $326,969.60 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.79 to 60.77, inclusive. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,655 | $59.39 | $514,020.45 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,345 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.79 to 59.78 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-008245 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,010 | $59.99 | $120,579.90 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.91 to 60.06, inclusive. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,280 | $59.20 | $312,576.00 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.90 to 59.88, inclusive. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,710 | $58.58 | $451,651.80 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.88 to 58.87, inclusive. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,055 | $56.01 | $227,120.55 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.81 to 56.35, inclusive. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,945 | $55.36 | $605,915.20 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,055 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.78 to 55.75 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-006577 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,796 | $57.74 | $103,701.04 |
DisclosureSEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,910 | $56.60 | $277,906.00 |
DisclosureSEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,796 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.26 to 57.14, inclusive. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,294 | $55.77 | $462,556.38 |
DisclosureSEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,706 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.20 to 56.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,147 | $56.68 | $121,691.96 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.44 to 57.04, inclusive. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,420 | $55.96 | $527,143.20 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.44 to 56.39, inclusive. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,433 | $54.96 | $188,677.68 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,567 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.53 to 55.39, inclusive. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,700 | $59.99 | $101,983.00 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.98 to 60.07, inclusive. Read SEC document |
| January 27, 2021 Filed Jan 30, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,913 | $59.37 | $410,424.81 |
DisclosureSEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.97 to 59.874, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.